MERCK & CO. INC.
MRKNYSETrading Snapshot
- Day Range
- $139.21 – $142.40
- 52-Week Range
- $82.01 – $156.92
- Volume (shares)
- 8,193,716
- Avg Volume (shares)
- —
- Shares Outstanding
- 2.47B
- Next Earnings
- 2026-10-29
Fundamentals Snapshot
- Annual Revenue
- $64.93B
- Last Q Revenue
- $16.61B
- P/E Ratio
- 112.7
- P/S Ratio
- 5.4x
- EPS (TTM)
- $1.25
- Dividend Yield
- 2.32%
- Dilution (1yr)
- −2.1%
MERCK & CO. INC.
MRK
StockOtter · stockotter.spaceAbout MERCK & CO. INC.
Merck & Co., Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health. The Pharmaceutical segment is dedicated to human health, offering a broad spectrum of medicinal products. These cover crucial therapeutic areas such as oncology, acute hospital care, immunology, neuroscience, virology, cardiovascular conditions, and diabetes. This division also develops vital preventive vaccines for pediatric, adolescent, and adult populations. Meanwhile, the Animal Health segment focuses on the research, development, manufacturing, and marketing of veterinary medications, vaccines, and comprehensive health management solutions for animals. This division further provides innovative digital products designed for animal identification, traceability, and continuous monitoring. Merck's extensive clientele encompasses drug wholesalers, pharmacies, hospitals, and government agencies. It also serves managed healthcare organizations, including health maintenance organizations (HMOs) and pharmacy benefit managers, as well as various other institutional clients. Additionally, the company supplies products to individual physicians and their distributors, veterinarians, and livestock producers. The organization actively engages in strategic collaborations with companies such as AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., Ridgeback Biotherapeutics, and Gilead Sciences, Inc. These partnerships are specifically aimed at the joint development and commercialization of prolonged-acting therapies for HIV. Established in 1891, Merck & Co., Inc. maintains its corporate headquarters in Kenilworth, New Jersey.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Latest News & Updates
Brokers Suggest Investing in Merck (MRK): Read This Before Placing a Bet
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their r
3 Big Pharma Earnings Reports to Watch: Eli Lilly, Merck and Gilead
Eli Lilly's EPS estimate collapsed by a third in just 30 days, Merck faces a comparison it cannot repeat, and Gilead is burning through cash fast.
Asset Management One Co. Ltd. Purchases 12,550 Shares of Merck & Co., Inc. $MRK
Asset Management One Co. Ltd. raised its position in Merck and Co., Inc. (NYSE: MRK) by 0.9% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,392,593 sha
4 Blue-Chip Dividend Stocks That Could Turn $200,000 Into Annual Retirement Income
Four blue-chip companies have quietly built dividend records spanning decades, but the real story is how a $200,000 split across them generates cash every quarter regardless of what the broader market decides to do next.
What's in Store for These 5 Drug/Biotech Stocks in Q3 Earnings?
Biotech earnings take center stage as Bristol Myers, Eli Lilly, Merck, AbbVie and Gilead Sciences prepare to report Q3'26 results.
Merck and Moderna's Cancer Vaccine Worked—Who Gets Paid?
Merck & Co. NYSE: MRK and Moderna NASDAQ: MRNA just cleared a bar no cancer vaccine had cleared before. Their personalized melanoma vaccine succeeded in a Phase 3 trial.